FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106560> ?p ?o ?g. }

• W4310106560 endingPage "9481" @default.
• W4310106560 startingPage "9480" @default.
• W4310106560 abstract "Background The anti-CD38 antibody daratumumab, currently approved for the treatment of patients with multiple myeloma, is also being explored for patients with acute lymphoblastic leukemia (ALL), whose blasts commonly express high levels of CD38. We assessed the safety and efficacy of Daratumumab-primed Venetoclax combined with CAGE in patients with relapsed/refractory T-ALL. Method This single-arm, open-label, phase I study enrolled patients with relapsed/refractory T-ALL who had received at least two lines of previous therapy and whose tumor cells express CD38. Patients received Daratumumab 12mg/kg intravenously on day 0, Venetoclax 100mg per os on days 0 to 7, Granulocyte colony-stimulating factor ( G-CSF) 150ug subcutaneous injection on days 0 to 7, Aclarubicin 7.5mg/m2 intravenously on days 1 to 7, Cytarabine 25 mg/m2 intravenously on days 1 to 7, Etoposide of 25 mg/m2 intravenously on days 1 to 7 of 28-day cycles for a maximum of two cycles or until documentation of minimal residual disease-negative complete response (as assessed by the investigator), disease progression, or unacceptable toxicity. For the CNS leukemia patients, intrathecal injection with dexamethasone 5mg, cytarabine 50mg and methotrexate 15mg should be done on days 1, 3, 5. Primary end point was CR rate and safety. Result Sixteen eligible patients were enrolled between October 2021 and May 2022, and all were followed up until July 31st, 2022. The median age of the 16 patients was 30 (15-72) years old. Eight patients were diagnosed with R/R T-ALL and 8 with R/R T-LBL at enrollment. High risk subtypes included early T-cell precursor (ETP)-ALL (n=8, 50%) and primary refractory disease (n=11, 68.8%). Eleven patients had a history of transplantation prior to enrollment, seven patients were allo-HSCT and four were auto-HSCT. Patients were heavily pretreated with a median of 7 (3-14) cycles of therapies before enrollment. The median duration from diagnosis to enrollment was 20 months (range 5.2-34.8). At enrollment, eleven patients had tumor cells infiltration of bone marrow. While 14 patients (6 T-ALL and 8 T-LBL) developed extramedullary disease, including diffuse involvement (n=5) or bulky mediastinal masses >7 cm in diameter (n=4), or central nervous system (CNS) involvement (n=6). For the regimen, the most common adverse events were leukocytopenia and infection. Hematologic grade 4 chemotherapy related adverse events (AE) included leukopenia, thrombocytopenia and neutropenia were observed in all patients (100%). The median duration of leukopenia, thrombocytopenia and neutropenia were 13 days, 14 days and 12 days, respectively. 100% patients experienced agranulocytosis with fever. Bacteremia Infection occurred in 4 patients (25%). Intestinal infection occurred in two patients (12.5%) and pulmonary infection occurred in three patients (18.75%). The median followed-up time was 4 months. Ten patients received one cycle chemotherapy and six patients received two cycles chemotherapy. Six patients got complete remission (CR) by one cycle chemotherapy. Three patients got complete remission (CR) by two cycles chemotherapy. The rate of CR and the objective remission rate (ORR) were 56.25% (n=9) and 62.5% (n=10) , respectively. Eight of eleven patients who had bone marrow involvement achieved minimal residual disease (MRD) negative CR (n=6, 54.5%) or MRD positive CR (n=2, 18.2%); Two patients (18.2%) with bone marrow involvement achieved partial remission (PR). The rate of ORR and CR for patients with bone marrow involvement were 90.9% and 72.7%, respectively. Six of ten patients who had extramedullar lymph nodes involvement achieved CR (60%); Two patients (20%) achieved PR. For the extramedullar lymph nodes involvement, the rate of ORR and CR were 80% and 60%, respectively. While only two of six patients who had CNS leukemia achieved CR (33.3%). Conclusions Daratumumab-primed Venetoclax combined with CAGE achieved a high remission rate for refractory/relapsed T-lymphoblastic leukemia/lymphoma patients with acceptable tolerability. The regimen could be a superior selection as tumor reduction bridged to CAR T or allo-HSCT therapy. The regimen presented better efficacy for bone marrow involvement and extramedullar lymph nodes involvement than CNS leukemia, as well should be revised to enhance the CNS prophylaxis." @default.
• W4310106560 created "2022-11-30" @default.
• W4310106560 creator A5003468549 @default.
• W4310106560 creator A5009334010 @default.
• W4310106560 date "2022-11-15" @default.
• W4310106560 modified "2023-10-01" @default.
• W4310106560 title "Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: Single-Arm, Open-Label, Phase I Study" @default.
• W4310106560 doi "https://doi.org/10.1182/blood-2022-165210" @default.
• W4310106560 hasPublicationYear "2022" @default.
• W4310106560 type Work @default.
• W4310106560 citedByCount "0" @default.
• W4310106560 crossrefType "journal-article" @default.
• W4310106560 hasAuthorship W4310106560A5003468549 @default.
• W4310106560 hasAuthorship W4310106560A5009334010 @default.
• W4310106560 hasBestOaLocation W43101065601 @default.
• W4310106560 hasConcept C126322002 @default.
• W4310106560 hasConcept C142424586 @default.
• W4310106560 hasConcept C143998085 @default.
• W4310106560 hasConcept C2776063141 @default.
• W4310106560 hasConcept C2776364478 @default.
• W4310106560 hasConcept C2777938653 @default.
• W4310106560 hasConcept C2778020697 @default.
• W4310106560 hasConcept C2778461978 @default.
• W4310106560 hasConcept C2779675984 @default.
• W4310106560 hasConcept C2781107101 @default.
• W4310106560 hasConcept C2781119759 @default.
• W4310106560 hasConcept C2909962599 @default.
• W4310106560 hasConcept C3019800554 @default.
• W4310106560 hasConcept C31760486 @default.
• W4310106560 hasConcept C535046627 @default.
• W4310106560 hasConcept C71924100 @default.
• W4310106560 hasConcept C86803240 @default.
• W4310106560 hasConcept C87355193 @default.
• W4310106560 hasConceptScore W4310106560C126322002 @default.
• W4310106560 hasConceptScore W4310106560C142424586 @default.
• W4310106560 hasConceptScore W4310106560C143998085 @default.
• W4310106560 hasConceptScore W4310106560C2776063141 @default.
• W4310106560 hasConceptScore W4310106560C2776364478 @default.
• W4310106560 hasConceptScore W4310106560C2777938653 @default.
• W4310106560 hasConceptScore W4310106560C2778020697 @default.
• W4310106560 hasConceptScore W4310106560C2778461978 @default.
• W4310106560 hasConceptScore W4310106560C2779675984 @default.
• W4310106560 hasConceptScore W4310106560C2781107101 @default.
• W4310106560 hasConceptScore W4310106560C2781119759 @default.
• W4310106560 hasConceptScore W4310106560C2909962599 @default.
• W4310106560 hasConceptScore W4310106560C3019800554 @default.
• W4310106560 hasConceptScore W4310106560C31760486 @default.
• W4310106560 hasConceptScore W4310106560C535046627 @default.
• W4310106560 hasConceptScore W4310106560C71924100 @default.
• W4310106560 hasConceptScore W4310106560C86803240 @default.
• W4310106560 hasConceptScore W4310106560C87355193 @default.
• W4310106560 hasIssue "Supplement 1" @default.
• W4310106560 hasLocation W43101065601 @default.
• W4310106560 hasOpenAccess W4310106560 @default.
• W4310106560 hasPrimaryLocation W43101065601 @default.
• W4310106560 hasRelatedWork W2530744085 @default.
• W4310106560 hasRelatedWork W2607337979 @default.
• W4310106560 hasRelatedWork W2781552270 @default.
• W4310106560 hasRelatedWork W2914292410 @default.
• W4310106560 hasRelatedWork W3007944408 @default.
• W4310106560 hasRelatedWork W3044534343 @default.
• W4310106560 hasRelatedWork W3211928898 @default.
• W4310106560 hasRelatedWork W4200120015 @default.
• W4310106560 hasRelatedWork W4280563108 @default.
• W4310106560 hasRelatedWork W2531692626 @default.
• W4310106560 hasVolume "140" @default.
• W4310106560 isParatext "false" @default.
• W4310106560 isRetracted "false" @default.
• W4310106560 workType "article" @default.